Stockreport

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com
PDF Advancing Phase 1 program in Chagas Disease; Phase 2 planning underwayClinical-stage M. abscessus program advancing through investigator-initiated trial (IIT)First of tw [Read more]